Compare · DVA vs PGNY
DVA vs PGNY
Side-by-side comparison of DaVita Inc. (DVA) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $11.34B, about 5.7x PGNY ($1.98B).
- Over the past year, DVA is up 28.2% and PGNY is up 14.2% - DVA leads by 14.0 points.
- DVA has been more active in the news (13 items in the past 4 weeks vs 6 for PGNY).
- PGNY has more recent analyst coverage (25 ratings vs 14 for DVA).
- Company
- DaVita Inc.
- Progyny Inc.
- Price
- $177.63+0.67%
- $25.84+1.55%
- Market cap
- $11.34B
- $1.98B
- 1M return
- -24.60%
- -18.21%
- 1Y return
- +28.15%
- +14.16%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 13
- 6
- Recent ratings
- 14
- 25
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest DVA
- DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
- Director Hollar Jason M. was granted 278 shares, increasing direct ownership by 4% to 6,883 units (SEC Form 4)
- Director Desoer Barbara J was granted 278 shares (SEC Form 4)
- Director Pullin Dennis W was granted 278 shares, increasing direct ownership by 10% to 2,949 units (SEC Form 4)
- Director Moore Gregory J. was granted 278 shares, increasing direct ownership by 4% to 8,091 units (SEC Form 4)
- Director Yale Phyllis R was granted 278 shares, increasing direct ownership by 3% to 9,803 units (SEC Form 4)
- Director Schechter Adam H was granted 278 shares, increasing direct ownership by 5% to 5,970 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 278 shares (SEC Form 4)
- Director Arway Pamela M was granted 278 shares, increasing direct ownership by 1% to 27,223 units (SEC Form 4)
- DaVita upgraded by TD Cowen with a new price target
Latest PGNY
- Wells Fargo initiated coverage on Progyny with a new price target
- Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- SEC Form 10-Q filed by Progyny Inc.
- Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Progyny, Inc. Announces Second Quarter 2026 Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- Progyny downgraded by Barclays with a new price target
- Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
- Chief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation